From APhA website, published April 16: Patients are likely to come to pharmacists with questions and concerns regarding the Janssen (Johnson & Johnson, J&J) vaccine. The American Pharmacists Association (APhA) spoke with Stephan Foster, PharmD, FAPhA, APhA liaison to CDC’s Advisory Committee on Immunization Practices (ACIP), to get his thoughts on talking to patients about the J&J vaccine with the information available so far.
“What we know is that there were six cases in the United States of patients with cerebral venous sinus thrombosis (CVST) with thrombocytopenia,” said Dr. Foster. “CVST is rare in itself, but when you combine it with thrombocytopenia, it’s even more rare.”
Related: The European Union’s drug regulatory agency says it found a “possible link” between the J&J vaccine and rare blood clots, but reiterates that the benefits outweigh the risks (published April 20) Related: FDA inspection finds numerous problems at Baltimore factory intended to make J&J vaccine (published April 21)
Print Page
Email to a Friend